Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

Explore how next-generation analytical methods empower researchers with accurate, consistent AAV titer measurement for gene ...

Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, ...

A trial of lenacapavir showed 100% protection against HIV infection. But cuts to foreign aid and criticism over its pricing put the brakes on a worldwide rollout. Elna Schütz asks if we’re now seeing ...

GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Gilead Sciences shows strong growth potential with raised guidance, patent protection, and undervaluation. Learn more about ...

Viruses in water pose major public health threats, yet their structural diversity makes them unequally susceptibility to ...

Ancient viral fossils buried in our DNA are offering fresh clues about how today’s respiratory pathogens infect and spread.

Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401. Click here to read why NGNE stock ...

Health researchers aim to develop personalized strategy for language acquisition in kids with Down syndrome, enhancing their ...

In addition to PRRSV, the key reagents are available for African swine fever virus and porcine epidemic diarrhea virus.

A slum-based healthcare rights organisation wants the new HIV prevention drug to be first rolled out in poor neighbourhoods to bear much of the epidemic’s brunt. The lobby also wants healthcare ...